Merck Wnt DME trial success lifts Surrozen pre-market on read-through

 

• Merck at 6:45 AM ET said remigromig met BRUNELLO Phase 2b/3 primary endpoint in DME.
• Both doses were non-inferior to ranibizumab on 52-week best-corrected visual acuity.
• Higher PDR, vitreous hemorrhage and dropouts versus control noted in the Wnt monotherapy.
• Traders viewed the Wnt validation plus safety caveats as bullish for SRZN's VEGF-combo SZN-8141.
• Biotech posts on X highlighted the mechanism success as a positive read-through for Surrozen.
• No Surrozen press release, 8-K or analyst note appeared after the prior close.
• The 62% gap far exceeds the stock's 7% average daily range, matching the catalyst scale.

https://finviz.com/stock?t=SRZN&p=d